Clinical trials: Hot Flushes
Menopause, Hot Flashes
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes.
- Trial name
- NCT03192176
- Testing
- Fezolinetant
- Where
- 51 sites in United States
- Volunteers
- 356 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Cancer, Hot Flashes
Pregabalin in Treating Women With Hot Flashes
RATIONALE: Pregabalin may help relieve hot flashes in women with a history of breast cancer or those who have no history and do not wish to take estrogen therapy for fear of increased risk of breast cancer.
- Trial name
- NCT00702949
- Testing
- pregabalin
- Where
- 209 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Fatigue
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
RATIONALE: Paced breathing may be an effective way to reduce the number and severity of hot flashes in women who have survived breast cancer.
- Conditions
- Breast Cancer, Fatigue, Hot Flashes, Sleep Disorders
- Trial name
- NCT00569166
- Testing
- Paced breathing (15 min once daily, 6 breaths/min), Paced breathing (15 min twice daily, 6 breaths/min), Paced breathing (10 min once daily, 14 breaths/min)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Hot Flashes
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 2 (NCT04003142)
- Testing
- Fezolinetant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 501 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Moderate to Severe Vasomotor Symptoms in Postmenopausal, Women
A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women.
- Trial name
- NCT01015677
- Testing
- MK-6913, 17-β estradiol, MK-6913 25 mg
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Hot Flashes
Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
This is an exploratory 8-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mgin subjects with moderate to severe postmenopausal vasomotor symptoms (VMS), defined…
- Trial name
- NCT00786188
- Testing
- Brisdelle (paroxetine mesylate), Sugar pill
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- Noven Therapeutics
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer…
- Trial name
- OASIS-4 (NCT05587296)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 102 sites in Austria, Belgium and 14 more
- Volunteers
- 474 people
- Sponsor
- Bayer
Postmenopausal Symptoms
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- N30-003 (NCT01361308)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 74 sites in United States
- Volunteers
- 614 people
- Sponsor
- Noven Therapeutics
Vasomotor Symptoms; Hot Flashes
Study of Erenumab (AMG 334) in Women With Hot Flashes
The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.
- Trial name
- NCT01890109
- Testing
- Erenumab
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amgen
Hot Flashes
Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women
- Trial name
- NCT00777023
- Testing
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg
- Where
- 45 sites in United States
- Volunteers
- 565 people
- Sponsor
- Depomed
Hormone Replacement Therapy
Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.
Multicenter, double-blind, controlled, parallel group, randomized study to compare the clinical benefit of Estradiol acetate tablets, estradiol tablets and conjugated equine estrogen tablets, each administered orally, once daily…
- Trial name
- NCT01070979
- Testing
- Estradiol acetate, Estradiol, Conjugated equine estrogens
- Where
- 32 sites in United States
- Volunteers
- 249 people
- Sponsor
- Warner Chilcott
Hot Flashes
Breathe for Hot Flashes Randomized Controlled Trial
Background: Paced respiration has been internationally recommended for vasomotor symptom management despite limited empirical evidence.
- Trial name
- NCT00819182
- Testing
- Paced respiration
- Where
- United States
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Indiana University
Hot Flashes
Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Estradiol treatment is effective at reducing vasomotor symptoms (eg hot flushes) in postmenopausal women. This study will evaluate the safety and efficacy of Evamist.
- Trial name
- NCT01389102
- Testing
- Estradiol transdermal one 90 μL spray, Estradiol transdermal spray, two 90 μL sprays, Estradiol transdermal three 90 μL sprays
- Where
- 43 sites in United States
- Volunteers
- 454 people
- Sponsor
- Lumara Health, Inc.
Vasomotor Symptoms Associated With Menopause, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the…
- Trial name
- OASIS-3 (NCT05030584)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 86 sites in United States, Belgium and 7 more
- Volunteers
- 628 people
- Sponsor
- Bayer
Vasomotor Symptoms, Hot Flashes
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
- Trial name
- NCT00446199
- Testing
- 0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg)
- Where
- 76 sites in United States
- Volunteers
- 735 people
- Sponsor
- Bayer
Hot Flashes, Menopause
Reducing the Experience of Menopausal Symptoms Through Temperature
The purposes of this study are to obtain preliminary evidence on the efficacy of a cooling mattress pad in reducing subjective hot flashes for peri and postmenopausal women experiencing menopausal hot flashes, and to obtain…
- Trial name
- REST (NCT03937466)
- Testing
- Cooling mattress pad
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
Hot Flashes, Menopause
MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
The primary objective of this study is to determine the efficacy of both low-dose oral (by mouth) 17-ß-estradiol and the non-hormonal drug venlafaxine XR compared to placebo in reducing hot flashes.
- Conditions
- Hot Flashes, Menopause, Vasomotor Disturbance
- Trial name
- NCT01418209
- Testing
- Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR
- Where
- 4 sites in United States
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Breast Carcinoma, Ductal Breast Carcinoma In Situ
Oxybutynin Chloride in Managing Hot Flashes
This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy.
- Conditions
- Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02961790
- Testing
- Oxybutynin Chloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Academic and Community Cancer Research United
Vasomotor Symptoms, Hot Flashes
HIRREM Hot Flashes Study
The purpose of this research study is to determine the effects of a technique called High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM®), for women in any stage of menopause, who are experiencing…
- Conditions
- Vasomotor Symptoms, Hot Flashes, Menopause
- Trial name
- NCT03512002
- Testing
- HIRREM, Continued Current Care
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Cancer Survivor
Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer
RATIONALE: Magnesium oxide may help relieve hot flashes in women with cancer. PURPOSE: This phase II trial is studying how well magnesium oxide works in treating hot flashes in menopausal women with cancer.
- Conditions
- Breast Cancer, Cancer Survivor, Hot Flashes, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01008904
- Testing
- magnesium oxide, questionnaire administration, quality-of-life assessment
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University